BSX vs RNA · P/E 20, rev $10.65B vs rev $22.6M
Boston Scientific Corp (BSX) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Boston Scientific Corp (BSX) is a medical devices company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported BSX revenue for 2026-06-30 was $10.65B. Net income was $2.24B. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
BSX currently screens at market cap $71.81B and trailing P/E 20.2. RNA currently screens at market cap $217.5M.
Not investment advice. Open the BSX and RNA stock pages for the full models.
Not investment advice.